BioCryst Pharmaceuticals, Inc. (FRA:BO1)
Germany flag Germany · Delayed Price · Currency is EUR
6.06
+0.02 (0.36%)
At close: Dec 1, 2025

BioCryst Pharmaceuticals Ratios and Metrics

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
Nov '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
1,3041,5051,1102,0032,1911,075
Upgrade
Market Cap Growth
-12.88%35.56%-44.58%-8.62%103.78%127.05%
Upgrade
Enterprise Value
1,7091,9991,5152,2792,2891,024
Upgrade
Last Close Price
6.047.325.5710.3111.755.67
Upgrade
PS Ratio
2.553.463.707.9015.8673.85
Upgrade
PB Ratio
-3.94-3.27-2.69-7.26-23.29-68.29
Upgrade
EV/Sales Ratio
3.304.595.058.9916.5670.34
Upgrade
EV/EBITDA Ratio
24.001194.32----
Upgrade
Debt / Equity Ratio
-1.76-1.77-1.86-2.52-5.54-14.51
Upgrade
Debt / EBITDA Ratio
8.27208.58----
Upgrade
Asset Turnover
1.280.900.620.480.340.07
Upgrade
Inventory Turnover
29.6010.117.7112.0018.93-
Upgrade
Quick Ratio
1.602.492.974.505.182.93
Upgrade
Current Ratio
1.872.633.314.895.463.07
Upgrade
Return on Equity (ROE)
------1925.37%
Upgrade
Return on Assets (ROA)
10.31%-0.16%-11.57%-16.30%-24.07%-41.60%
Upgrade
Return on Capital (ROIC)
14.46%-0.21%-14.70%-19.88%-29.76%-55.37%
Upgrade
Return on Capital Employed (ROCE)
30.20%-0.40%-26.90%-33.40%-36.70%-74.10%
Upgrade
Earnings Yield
-0.57%-5.71%-18.47%-11.55%-7.39%-13.90%
Upgrade
FCF Yield
3.13%-3.41%-7.93%-7.63%-5.80%-10.31%
Upgrade
Buyback Yield / Dilution
-1.84%-7.54%-3.38%-3.79%-7.08%-44.70%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.